Professor David Handelsman trained in Medicine, Endocrinology and Research, becoming Professor of Reproductive Endocrinology and Andrology at the University of Sydney in 1996.
David was the founding director of the ANZAC Research Institute and of Australia’s first Andrology Department at Concord Hospital. He was President and is Life Member of the Endocrine Society of Australia and of the Society for Reproductive Biology, and is a Fellow of the Academy of Health and Medical Sciences. He has served on the Australian Drug Evaluation Committee, the WHO Human Reproduction Program and the World Anti-Doping Agency’s Health, Medicine and Research Committee.
David’s research into androgen physiology, pharmacology and toxicology spans basic, clinical and public health domains, including major input into the design, monitoring and reporting of the two landmark WHO male contraception studies. He was also Principal Investigator in the proof-of-principle study that established the androgen-progestin combination as the most effective form of hormonal male contraception.